Myricx Bio Appoints Mohit Rawat as CEO and Expands Global Team Ahead of Clinical Entry

London, September 22, 2025 (Globe Newswire) -- Myricx Bio, a private biotech developing a novel class of N-myristoyltransferase inhibitor (NMTi) payloads for antibody-drug conjugates (ADCs), named Boston-based Mohit Rawat as Chief Executive Officer and member of its Board. Rawat, formerly President and Chief Business Officer at Fusion Pharmaceuticals (acquired by AstraZeneca for $2.4B), brings over two decades of leadership in oncology drug development, commercial strategy, and business development. The company also strengthened its senior team across the U.S. and U.K. as it prepares to advance its lead NMTi-ADC candidate into the clinic, supported by its £90 million ($114 million) Series A financing led by top global investors.

Read full article here.